Pune: India will benefit from the initial stockpile of about 40-50 million 'Covishield' vaccines developed by the Serum Institute of India (SII) once the company gets the regulatory approval to roll out the vaccine for the masses.
After getting the green signal from the Drug Controller General of India (DCGI), SII will require the World Health Organisation's (WHO) pre-qualification to export the vaccine to other countries that may take at least a month.
This may benefit India as it will get the first batch of the Oxford-AstraZeneca vaccine that has been developed at SII's Pune plant.
The world's largest vaccine maker by volume, SII has already manufactured 50 million doses of Covishield vaccine on at-risk funding. Overall, the vaccine giants aim to develop 3.2 billion doses of coronavirus vaccines at its facilities in India.
SII chief executive Adar Poonawalla has said the vaccine candidate could get approval by next week and it may be rolled out for the masses in January.
The company is ramping up capacity every week, he said.
He said all the requisite data has been submitted to the drug regulatory authorities in both India and the UK. He hoped the approval could come around the same time in both the countries.